AXIM - AXIM Biotechnologies, Inc.
| Previous Close | 0.4225 |
| Open | 0.4000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3700 - 0.4350 |
| 52 Week Range | 0.3560 - 2.5000 |
| Volume | 27,655 |
| Avg. Volume | 52,923 |
| Market Cap | 26M |
| Beta (3Y Monthly) | -5.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
The Week In Cannabis: A Federal Legalization Bill, Earnings Reports And A Tax Hike In California
For the first time ever, a congressional committee in the U.S. has voted on a cannabis legalization bill. The law in question, the Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2019, passed the House Judiciary Committee Wednesday in a 24-10 vote.
- GlobeNewswire
New Notice of U.S. Patent Allowance Granted to Axim® Biotechnologies for Suppository Formulations Comprising Cannabinoids
NEW YORK, Nov. 21, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.
- Benzinga
The Week In Cannabis: Hexo Postpones Q4 Report, Rapinoe Teams With CBD Brand, Sanders Unveils Legalization Plan
Business, finance and policy leaders from around the globe convened this week in Chicago for the Benzinga Cannabis Capital Conference to hear from the main voices in the space, from Bruce Linton, executive chairman of Gage Cannabis, and Jessica Billingsley, CEO of Akerna Corp (NASDAQ: KERN), to Tim Seymour, Jon Najarian and Jim Belushi. The corporate world continued to suffer, as more big public companies continued to put out bad news, including HEXO Corp (NYSE: HEXO) postponing its fourth-quarter report and announcing considerable layoffs — and at the same time launching a $70 million private placement.
- GlobeNewswire
AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
NEW YORK, Oct. 22, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development,.
- GlobeNewswire
AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting
(“AXIM® Biotech,” “AXIM” or “the Company”) (AXIM), a world leader in cannabinoid research and development, today announced that it has signed a cultivation agreement with a top hemp farm in North Carolina to establish the Company’s first domestic industrial hemp source.
- Benzinga
The Week In Cannabis: Big Pharma Makes Moves, Diddy & Wahlberg Go After CBD, Medicine Man Continues M&A Spree
This week, we saw Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) make a big move in the cannabis industry, through a distribution deal between its subsidiary Salomon, Levin, Elstein, and InterCure Ltd ...
- PR Newswire
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies
SAN DIEGO , Sept. 12, 2019 /PRNewswire/ -- Medical Marijuana, Inc . (OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...
- GlobeNewswire
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
(“AXIM® Biotech,” “AXIM” or “the Company”) (AXIM), a world leader in cannabinoid research and development, announced today that its contract manufacturer Eurofins Amatsigroup has begun manufacturing AXIM’s patented cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), for use in the Company’s upcoming clinical studies on cannabis as a treatment for chemotherapy related symptoms. According to the Center of Disease Control and Prevention (CDC), about 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic each year with an average cost of $100,000 per patient per year. Chemotherapy has been proven to be an effective treatment to kill cancer cells but in the process causes damage to other cells and tissues in the body.
- GlobeNewswire
New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids
NEW YORK, Aug. 08, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today.
- Benzinga
Cannabinoid R&D Updates: Medical Marijuana Inc And Axim Biotech
Medical Marijuana, Inc. (OTC: MJNA) subsidiary Kannaway has entered a strategic partnership with Endocanna Health, a research and development biotechnology company specializing in endocannabinoid DNA testing and personalization. Under the terms of the agreement, Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits and license its proprietary DNA technology to Kannaway.
- GlobeNewswire
AXIM® Biotechnologies Launches AXIM® Wellness Division Focused on Cannabinoid-Based Nutraceutical Products and Announces New Product Pipeline
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has launched its AXIM® Wellness division that will be focused on bringing consumers premium cannabinoid-based nutraceutical products. AXIM® Wellness division will address the high demand for cannabinoid-based solutions worldwide through a series of patented nutraceutical products.
- GlobeNewswire
AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months
NEW YORK, July 11, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.
- GlobeNewswire
AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division
NEW YORK, July 09, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.
- PR Newswire
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner
NEW YORK , June 26, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA ) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...
- GlobeNewswire
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease
NEW YORK, June 25, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, today.
- GlobeNewswire
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has garnered news coverage for an opinion article in top U.S. consumer publication FOX Business. The article was co-authored by John W. Huemoeller II, the Company’s CEO, and Dr. Stuart Titus, CEO of Medical Marijuana Inc., the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products.
- GlobeNewswire
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”) for the supply of the Company’s toothpaste and mouthwash containing cannabidiol (CBD) for its clinical trial for the treatment of periodontitis.
- PR Newswire
Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...
- GlobeNewswire
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company
NEW YORK, May 15, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today.
- CNW Group
Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th
Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th
- GlobeNewswire
AXIM® Biotechnologies to Present at Cannastocks 2019 Q1 Conference
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at Cannastocks 2019 Q1 Conference, taking place in New York on May 15, 2019. AXIM’s Chief Executive Officer John W. Huemoeller II will bring his expertise to this year’s event, presenting on the Company’s updated business strategy, proprietary controlled-release technology and patent on all chewing gum containing cannabinoids, including the Company’s patented flagship chewing gum products.
- PR Newswire
Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
NEW YORK , May 14, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , today announced that the Company's major investment ...